PALO ALTO, Calif. June 13, 2024’ Scilex Holding Company (Nasdaq: SCLX), renowned for its commitment to developing and commercializing non-opioid pain SCLX is set to make significant strides in the treatment of acute and chronic pain. The company recently announced its participation in the 66th Annual Scientific Meeting of the American Headache Society (AHS), scheduled to take place in San Diego, CA, from June 13 to 16, 2024. During this prestigious event, Scilex will present a poster on ELYXYB® (celecoxib oral solution), a promising solution aimed at alleviating pain.
ELYXYB®: A Pioneering Solution for Pain Management
ELYXYB® (celecoxib oral solution) represents a significant advancement in the treatment of pain. It is specifically formulated to offer effective relief, addressing the critical need for non-opioid pain management options. The presentation at the AHS Annual Scientific Meeting underscores Scilex’s ongoing efforts to bring innovative solutions to the forefront of medical science, ensuring better patient outcomes.
Recent Legal Milestone: Settlement Agreement with Takeda Pharmaceuticals
Adding to its array of accomplishments, Scilex Holding Company also made
Comments